Skip to main content
. Author manuscript; available in PMC: 2019 Oct 9.
Published in final edited form as: Sci Signal. 2018 Oct 9;11(551):eaat9773. doi: 10.1126/scisignal.aat9773

Fig. 5. In vivo efficacy of neratinib against HER2-amplified and mutant PDXs.

Fig. 5.

Antitumor effects of neratinib in xenografts bearing in ERBB2. Growth of patient-derived xenografts containing coincident ERBB2 amplification and HER2 D769Y mutation, in mice treated with vehicle (control), trastuzumab (10 mg/kg; ip; 2xwkly), lapatinib (100mg/kg daily) or neratinib (40mg/kg daily). Data are k means ± SEM from 8 mice each condition. P<0.001 by two-tailed Student’s t-test